Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine Announces Offering of Common Stock
08:21pm, Tuesday, 23'rd Jun 2020
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of its common stock in an underwritten public offering. Editas Medic
Why CRISPR Therapeutics Stock Just Popped Another 5% | The Motley Fool
08:08pm, Tuesday, 23'rd Jun 2020
Two bullish analyst recommendations in less than 24 hours boost the stock price more than 9%.
CRISPR Stock Is a Worthwhile Investment in Transformative Science
02:50pm, Monday, 22'nd Jun 2020
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stock.
Editas Medicine Inc (NASDAQ:EDIT) Given Average Rating of “Hold” by Analysts
02:06am, Sunday, 21'st Jun 2020
Shares of Editas Medicine Inc (NASDAQ:EDIT) have been assigned a consensus rating of “Hold” from the ten brokerages that are presently covering the stock, MarketBeat.com reports. Six research anal
Editas Medicine (NASDAQ:EDIT) Trading Up 8.6%
05:50am, Saturday, 20'th Jun 2020
Editas Medicine Inc (NASDAQ:EDIT)’s share price rose 8.6% during mid-day trading on Thursday . The stock traded as high as $33.55 and last traded at $32.45, approximately 1,818,154 shares changed ha
Editas (EDIT) in Focus: Stock Moves 8.6% Higher
12:41pm, Friday, 19'th Jun 2020
Editas (EDIT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Equities Analysts Issue Forecasts for Editas Medicine Inc’s Q3 2020 Earnings (NASDAQ:EDIT)
06:20am, Friday, 19'th Jun 2020
Editas Medicine Inc (NASDAQ:EDIT) – Stock analysts at SunTrust Banks issued their Q3 2020 earnings estimates for shares of Editas Medicine in a research note issued to investors on Thursday, June 18
Editas Medicine (NASDAQ:EDIT) Upgraded at BidaskClub
01:28am, Friday, 19'th Jun 2020
Editas Medicine (NASDAQ:EDIT) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports. Several
NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour
12:00am, Friday, 19'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: Exxon Mobil Corp, Natural Gas Futures, Cirrus Logic Inc, DSP Group Inc. Read Zacks Investment Research's latest article on Investing.com
Genomics: How A Cutting-Edge Field Is Fighting COVID-19
09:05am, Thursday, 18'th Jun 2020
In early January, researchers identified an irregular, lethal pneumonia spreading through China as the disease we now know as COVID-19. Global efforts to identi
Editas Medicine Target of Unusually High Options Trading (NASDAQ:EDIT)
01:44am, Thursday, 18'th Jun 2020
Editas Medicine Inc (NASDAQ:EDIT) was the target of unusually large options trading activity on Wednesday. Stock investors bought 3,252 call options on the stock. This is an increase of approximately
Nature-Inspired CRISPR Enzyme Discoveries Vastly Expand Genome Editing
11:35am, Tuesday, 16'th Jun 2020
Applied computational biology discoveries vastly expand the range of CRISPR’s access to DNA sequences. In nature, bacteria use CRISPR as an adaptive immune system to protect themselves against virus
A Guide to Investing in Gene Editing Stocks
05:59am, Tuesday, 16'th Jun 2020
If we had to pick one disruptive technology that has the most potential to change mankind, it would be synthetic biology (synbio). A critical component of synbio is gene editing. You cannot have one w
Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics | The Motley Fool
10:00am, Sunday, 14'th Jun 2020
Each company aims to use its genome editing platform to treat disease, but which has an edge?
Editas Medicine (NASDAQ:EDIT) Trading Up 7.9%
04:00am, Sunday, 14'th Jun 2020
Editas Medicine Inc (NASDAQ:EDIT)’s stock price was up 7.9% during mid-day trading on Friday . The company traded as high as $27.49 and last traded at $26.99, approximately 756,356 shares traded han
